Ulipristal

Cat. No.: HY-14959

CAS No.: 159811-51-5

Molecular Formula: $C_{28}H_{35}NO_3$

Molecular Weight: 433.58

Target: Progesterone Receptor

Pathway: Others

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 250 mg/mL (576.59 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3064 mL	11.5319 mL	23.0638 mL
	5 mM	0.4613 mL	2.3064 mL	4.6128 mL
	10 mM	0.2306 mL	1.1532 mL	2.3064 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 6.25 mg/mL (14.41 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 6.25 mg/mL (14.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ulipristal (CDB 3236) is a selective progesterone receptor modulator (SPRM). Ulipristal binds to the progesteron receptor, thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system[1].

In Vivo

Ulipristal (CDB 3236) may suppress the growth of uterine leiomyomatosis. By inhibiting or delaying ovulation and effecting endometrial tissue, ulipristal can be used as an emergency contraception[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. LIANA PLES, et al. Is Ulipristal Acetate a Liver Toxic Biomolecule? Toxicity assessment of ulipristal acetate. REV.CHIM.(Bucharest).

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA